

APPLICATION NOTES

Product: TRANS-HSC

A PROGENITOR CELLULAR PLATFORM – A TOOL TO HUMANIZE PRE-CLINICAL MOUSE MODELS

Authors: L Krishna (PhD), A Pallepati MSc, S Dravida PhD

Product Description:

TRANS-HSC is an *invitro* (human cord blood) sourced primary progenitor/stem cell based platform model composed of magnetically fractionated CD34+ cell aggregates. Each unit is tested negative for HIV-1, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi.

Available in frozen condition (in DMSO). Ready to use with customized number per vial.

Injectable TRANS-HSC to Humanize:



Recommended:

As a tool to develop preclinical translational mouse models in Infectious diseases

Measurable end points:

Mirror patient therapy or examine alternate therapies on models developed using TRANS-HSC



Purity:

The purity of CD34+ cells is \geq 90% evaluated in flow cytometer





Stability & Storage:

Product stable at -80°C or colder for 8 months from date of receipt. Thawed units must be used immediately.

Instructions to use TRANS-HSC:

Thaw, Decant, Add medium to acclimatize, Centrifuge, Reconstitute the pellet to inject

Advantages using TRANS-HSC:

Development of multiple hematopoietic lineages; Primary immune responses in the model developed

Ready to use; No culturing procedure involved to use; No tissue culture facility required to use

Features:

Fractionated sterile CD34+ cell aggregates packaged as injectable units; Processed, pooled batch wise to be Bioburden free

Benefits:

Humanized mouse models developed with TRANS-HSC combine the value of animal models with the accuracy of human immune responses

Made available from abundantly sourced biological material

TRANS-HSC for:

Type of testing:

To develop humanized mouse models representing human Infectious diseases

Level of assessment:

Test material's druggability to treat or cure human infectious diseases on the pre-clinical research model developed injecting TRANS-HSC

Purpose of testing:

Exploratory preclinical evaluation of chemical library, hits, leads, investigational new drugs for human application and compatibility